Skip to main content
Premium Trial:

Request an Annual Quote

BD Completes $275M Acquisition of HandyLab

NEW YORK (GenomeWeb News) – Becton Dickinson has completed its $275 million acquisition of molecular diagnostics firm HandyLab, the firm said today.

HandyLab sells the Jaguar molecular diagnostics system, which incorporates clinical sample preparation, nucleic acid extraction, microfluidic real-time PCR amplification and detection. The Ann Arbor, Mich.-based firm launched the system in November 2008.

BD said that it plans to place its BD GeneOhm assays for methicillin-resistant Staphylococcus aureus, Clostridium difficile, and vancomycin-resistant Enterococcus on the HandyLab platform and market them as the new BD Max system. It said that the BD Max system is an evolution of the current Jaguar system.

The acquisition follows an alliance between the firms begun earlier this year aimed at placing the GeneOhm tests on the Jaguar system.

BD announced the deal to acquire HandyLab last month, but it did not provide the purchase price at that time.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SAR-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.